HRSA delays until Oct. 1 the effective date of final rule on 340B drug ceiling prices
The Health Resources and Services Administration today delayed to Oct. 1 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. The final rule was subject to multiple delays since January. “The additional time provided to the public before the rule takes effect constitutes an extra quarter and will assist stakeholders in preparing to comply with these new program requirements,” the notice states.
Related News Articles
Perspective
More than 34.1 million Americans were enrolled in a Medicare Advantage plan in 2025, accounting for 54% of all Medicare beneficiaries. We have seen enrollment…
Headline
The Department of Health and Human Services Feb. 5 in a court filing said it would scrap its current 340B Rebate Model Pilot Program and potentially restart…
Headline
A new AHA blog published Feb. 3 discusses how the 340B Drug Pricing Program serves as an effective solution to some of the nation’s most persistent and…
Blog
Many Americans may be unaware that the services they rely on every day through their local hospital are supported by a program called the 340B Drug Pricing…
Headline
A KFF analysis released Jan. 28 found that Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, an increase…
Headline
The Centers for Medicare & Medicaid Services Jan. 26 released proposed changes to Medicare Advantage plan capitation rates and Part D payment policies for…